News
June 1, 2023
One year later, highest almetric score for any paper published in Nature Cancer!
Dallas, Texas. June 1, 2023: One year after its online publication, we are pleased to note that our manuscript titled “Targeting LIPA independent of its lipase activity is a therapeutic...
April 18, 2023
Positive preclinical data presented at AACR 2023
Dallas, Texas. April 18, 2023: Etira is pleased to announce that multiple abstracts related to their licensed products showed encouraging preclinical activity in metastatic breast cancer and ovarian cancer. The...
April 17, 2023
Etira founder Dr. Ratna Vadlamudi honored with the prestigious 2023 Distinguished Research Scholar Award
Dallas, Texas. April 17, 2023: We are excited to congratulate one of our founders, Dr. Ratna Vadlamudi, Professor and Vice Chair for Research, Division of Reproductive Research, Department of Obstetrics...
December 9, 2022
Preclinical data on TNBC presented at SABCS 2022
Dallas, Texas. December 9, 2022: Etira is pleased to report the abstract related to ERX-41 validating its activity in Triple negative breast cancer was presented at the San Antonio Breast...
October 31, 2022
Etira founder Dr. Jung-Mo Ahn highlighted in local press
Dallas, Texas. October 31, 2022. We are pleased to share two news articles from Dallas that describe how our brilliant chemist and founder, Dr. Jung-Mo Ahn discovered ERX-41. In his...
October 10, 2022
Oncology Times Highlights ERX-41
Dallas, Texas. October 10, 2022: etiraRx's lead drug candidate, ERX-41 has been highlighted in the most recent edition of Oncology Times. In an article entitled "Molecule Targets Vulnerability in Triple-Negative...
September 23, 2022
Etira selected as a 2022 BioNTX rising star
Dallas Texas, September 23, 2022. We are pleased to announce that Etira has been selected as a 2022 BioNTX rising star. The BioNTX iC³ Life Science Summit is a two-day...
July 10, 2022
ERX-41 Paper image selected for Nature Cancer cover
Dallas, Texas. July 7, 2022: On the cover of the July 2022 issue of Nature cancer is an image of the endoplasmic reticulum within a cell. Image courtesy of Dr....
July 1, 2022
Scientific News Media Features the Discovery of ERX-41, the Novel Mechanism of Action and Novel Molecular Target
Dallas, Texas. July 1, 2022: Following the publication of the article “Targeting LIPA independent of its lipase activity is a therapeutic strategy in solid tumors via induction of endoplasmic reticulum...
June 3, 2022
EtiraRx’s Licensed ERX-41 Identified as a Potential New Oral Therapy for Multiple Cancers, Company Prepares for Clinical Trials
Dallas, Texas. June 2, 2022: /PRNewswire/ -- A scientific team, led by the scientific founders of EtiraRx, has identified a small molecule, ERX-41, as a novel oral therapeutic agent that...